# Personalis, Inc. (PSNL) Stock Analysis: A 58.95% Potential Upside in Cancer Genomic Testing

- Link: https://www.directorstalkinterviews.com/personalis-inc-psnl-stock-analysis-a-58-95-potential-upside-in-cancer-genomic-testing/4121245655
- Published: 2026-03-20T11:30:28+00:00
- Author: Madison Wilson

Investors eyeing opportunities in the healthcare sector might want to take a closer
look at Personalis, Inc. (PSNL), a company making significant strides in the diagnostics
and research industry. With a focus on advanced cancer genomic tests, Personalis
offers promising technologies that cater to a wide array of clients, from pharmaceutical
giants to individual cancer patients. As the firm navigates the evolving landscape
of cancer diagnostics, it presents a compelling case for investment, coupled with
a notable analyst consensus indicating a potential upside of nearly 59%.

Personalis, with a market capitalization of $752.3 million, is headquartered in 
Fremont, California, and primarily serves the United States market. The company 
is renowned for its innovative products like NeXT Personal and ImmunoID NeXT, which
provide comprehensive insights into tumor biology, an area that is critical for 
developing personalized cancer therapies.

Currently trading at $7.19, Personalis has seen a modest price change of 0.23 (0.03%).
While its 52-week range shows fluctuations between $3.00 and $11.25, the stock’s
potential is underscored by analyst target prices ranging from $10.00 to $13.00,
with an average target of $11.43. These figures suggest a potential upside of 58.95%,
an attractive prospect for growth-focused investors.

Despite the promising outlook, Personalis faces challenges evident in its financial
metrics. The absence of a price-to-earnings ratio and a negative forward P/E of -
7.70 highlight ongoing profitability struggles. The company’s earnings per share(
EPS) of -0.91 and a return on equity of -35.02% further indicate that profitability
is not yet within reach. Moreover, Personalis’s free cash flow stands at an unfavorable-
$42,980,752.00, a factor that underscores the need for cautious optimism.

However, the company’s revenue growth of 3.20% suggests a positive trajectory, albeit
at a measured pace. Its strategic collaboration with Tempus AI, Inc. to enhance 
testing for colorectal cancer is a testament to its commitment to expanding its 
footprint in the oncological diagnostics space.

Technically, Personalis’s stock presents a mixed outlook. The 50-day moving average
of $8.67 is above its current trading price, while the 200-day moving average stands
at $7.47. The relative strength index (RSI) at 45.31 indicates the stock is neither
overbought nor oversold. However, the MACD and signal line, at -0.48 and -0.37 respectively,
point to bearish momentum, suggesting that investors should watch for potential 
buying opportunities if the price aligns with supportive technical signals.

Analyst sentiment towards Personalis remains predominantly positive, with six buy
ratings and one hold rating, and no sell ratings. This bullish stance reflects confidence
in the company’s ability to leverage its innovative products for future growth, 
despite current financial headwinds.

Personalis’s endeavors in cancer genomic testing position it as a potentially rewarding
investment in the healthcare sector, particularly for those willing to accept short-
term volatility for potential long-term gains. As the company continues to innovate
and expand its market presence, it remains a stock to watch for investors seeking
exposure to cutting-edge advancements in cancer diagnostics.

Share on: